1879 Impact of adjuvant trastuzumab (adjT) for early-stage (ES) breast cancer (BC) on clinical characteristics, survival and likelihood of durable complete response (DCR) of HER2-positive (HER2+) metastatic breast cancer (MBC): A 15-year single-institution cohort study
2015
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI